Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Merck & Co
(NY:
MRK
)
99.18
UNCHANGED
Streaming Delayed Price
Updated: 7:00 PM EST, Nov 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Merck & Co
< Previous
1
2
...
18
19
20
21
22
23
24
25
26
...
96
97
Next >
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024
January 05, 2024
Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain.
Via
Investor's Business Daily
3 reasons 2024 Moderna shareholders may party like it's 2021
January 05, 2024
With interest in Moderna Inc. stock picking up alongside news flow, investors could be in for some very healthy 2024 gains.
Via
MarketBeat
Exposures
COVID-19
Merck Announces Phase 3 Trial Initiations for Four Investigational Candidates From its Promising Hematology and Oncology Pipeline
January 05, 2024
From
Merck & Co., Inc.
Via
Business Wire
What the Options Market Tells Us About Merck & Co
December 26, 2023
Via
Benzinga
Looking Into Merck & Co's Recent Short Interest
December 25, 2023
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
January 04, 2024
Via
Benzinga
Stocks Edge Higher, Nasdaq Looks To Snap Skid
January 04, 2024
Stocks are attempting to regain their 2023 form today.
Via
Talk Markets
McDonald's Revenues Expected To Increase, Plus Merck And More On CNBC's 'Final Trades'
January 04, 2024
On CNBC’s "Halftime Report Final Trades," Joseph Terranova of Virtus Investment Partners named Merck & Co., Inc. (NYSE: MRK)
Via
Benzinga
2024 And Beyond – Exploring Six Investment Megatrends With Tema ETFs
January 04, 2024
A recent report from Tema ETFs, a leader in active exchange-traded funds (ETFs), offers a window into six emerging long-term megatrends. Its analysis provides a detailed account of evolving sectors,...
Via
Benzinga
Topics
ETFs
AMD To Rally Over 25%? Here Are 10 Top Analyst Forecasts For Thursday
January 04, 2024
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
Revenge of the Boring Stocks! Dividends Are Sexy Again.
January 03, 2024
Dividend stocks are leading the way in the first few days of 2024, indicating that boring is back! What that means for investors now.
Via
InvestorPlace
Tech Sell-Off Triggers Market Reset: Value Stocks Reach 7-Month High Versus Growth
January 03, 2024
U.S. stock market suffered worst start in two decades, tech sell-off led to cautious investor shift to value stocks, notably IUSV & IUSG ETFs + top gainers MRNA, VTRS, TNL, LVS & VAC.
Via
Benzinga
Topics
ETFs
Merck to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024
From
Merck & Co., Inc.
Via
Business Wire
10 Health Care Stocks Whale Activity In Today's Session
January 02, 2024
Via
Benzinga
There Are Only 5 Dow Stocks I Wouldn't Buy in 2024
December 29, 2023
There's a lot to like about Apple, Microsoft, and most of the Dow Jones Industrial Average components in 2024.
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
Moderna Stock Is Climbing Thanks to Merck, But Is It Still a Buy?
December 29, 2023
The pair's collaboration is making waves, and there's more to come.
Via
The Motley Fool
Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024
December 29, 2023
According to the Global Data report, the pharma sector in Q3 2023 witnessed deals worth $28 billion, down 28% from the $54 billion recorded in Q2 2023.
Via
Benzinga
Common Investing Mistake: Income Obsession (& More)
December 28, 2023
A common investing mistake is income obsession. Others are holding too many stocks and focusing on valuation to know if the price of a stock is right. Sounds familiar? Any of these mistakes hurts your...
Via
Talk Markets
Pharmaceutical Giants Brace for Showdown as Medicare Drug Price Negotiations Are Poised For 2024
December 28, 2023
2024 will mark a pivotal moment for the healthcare industry, particularly in drug pricing negotiations.
Via
Benzinga
January Effect: 3 Under-the-Radar Stocks Poised for a New Year Jump
December 24, 2023
Are you looking to profit from the January effect? Here are three under-the-radar stocks poised for a new year's jump.
Via
InvestorPlace
MarketBeat Week in Review – 12/18 - 12/22
December 23, 2023
The torrid stock market rally cooled down a little bit heading into the extended holiday weekend; we wish you a Happy Holiday season with friends and family
Via
MarketBeat
Topics
Economy
Exposures
Interest Rates
7 Small-Cap Stocks That Wall Street Loves for Good Reason
December 22, 2023
The market rally is showing signs of broadening to include small-cap stocks, here are seven that analysts are upgrading
Via
InvestorPlace
Patritumab Deruxtecan Granted Priority Review in the U.S. for Certain Patients with Previously Treated Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
December 22, 2023
From
Daiichi Sankyo
Via
Business Wire
7 Best Dow Jones Stocks to Buy for Conservative Investors
December 21, 2023
With many vagaries still surrounding the market, the best Dow Jones stocks for conservative investors offers a safer approach.
Via
InvestorPlace
Topics
Stocks
Exposures
US Equities
Merck's Chronic Cough Treatment Candidate Receives Second Time FDA Rejection
December 21, 2023
The FDA issued a Complete Response Letter (CRL) regarding Merck & Co Inc's (NYSE: MRK) New Drug Application (NDA) for gefapixant under development for the treatment of refractory chronic cough (RCC) or...
Via
Benzinga
Exposures
Product Safety
Merck Provides U.S. Regulatory Update on Gefapixant
December 20, 2023
From
Merck & Co., Inc.
Via
Business Wire
Merck to Participate in the Goldman Sachs Healthcare C-Suite Unscripted Conference
December 20, 2023
From
Merck & Co., Inc.
Via
Business Wire
Better Dividend Stock: Bristol Myers Squibb or Merck?
December 19, 2023
These two pharma stocks have sizable dividend yields. Which is the better buy right now?
Via
The Motley Fool
FDA Grants Priority Review to Merck’s New Biologics License Application for V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed to Protect Adults
December 19, 2023
From
Merck & Co., Inc.
Via
Business Wire
Jim Cramer Slams FTC Chair Lina Khan's Policies For Hampering Investor Returns: 'One-Woman Wrecking Crew For Your Stock Portfolio'
December 18, 2023
He posits that such actions have negatively impacted stock valuations.
Via
Benzinga
< Previous
1
2
...
18
19
20
21
22
23
24
25
26
...
96
97
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.